Status:
ACTIVE_NOT_RECRUITING
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Lead Sponsor:
Janssen Research & Development, LLC
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Eligibility Criteria
Inclusion
- Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention
- Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
- Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
- Total investigator global assessment (IGA) \>=3 at screening and baseline
- Candidate for phototherapy or systemic treatment for plaque psoriasis
Exclusion
- Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
- Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib, or to any of the excipients or components of the study intervention
- Major surgical procedure, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2027
Estimated Enrollment :
774 Patients enrolled
Trial Details
Trial ID
NCT06143878
Start Date
February 1 2024
End Date
June 1 2027
Last Update
January 9 2026
Active Locations (164)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Dermatology Specialists
Phoenix, Arizona, United States, 85006
2
Center for Dermatology and Plastic Surgery
Scottsdale, Arizona, United States, 85260
3
Johnson Dermatology
Fort Smith, Arkansas, United States, 72916
4
First OC Dermatology
Fountain Valley, California, United States, 92708